Literature DB >> 25493012

Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Sith Siramolpiwat1.   

Abstract

Portal hypertension (PH) plays an important role in the natural history of cirrhosis, and is associated with several clinical consequences. The introduction of transjugular intrahepatic portosystemic shunts (TIPS) in the 1980s has been regarded as a major technical advance in the management of the PH-related complications. At present, polytetrafluoroethylene-covered stents are the preferred option over traditional bare metal stents. TIPS is currently indicated as a salvage therapy in patients with bleeding esophageal varices who fail standard treatment. Recently, applying TIPS early (within 72 h after admission) has been shown to be an effective and life-saving treatment in those with high-risk variceal bleeding. In addition, TIPS is recommended as the second-line treatment for secondary prophylaxis. For bleeding gastric varices, applying TIPS was able to achieve hemostasis in more than 90% of patients. More trials are needed to clarify the efficacy of TIPS compared with other treatment modalities, including cyanoacrylate injection and balloon retrograde transvenous obliteration of gastric varices. TIPS should also be considered in bleeding ectopic varices and refractory portal hypertensive gastropathy. In patients with refractory ascites, there is growing evidence that TIPS not only results in better control of ascites, but also improves long-term survival in appropriately selected candidates. In addition, TIPS is a promising treatment for refractory hepatic hydrothorax. However, the role of TIPS in the treatment of hepatorenal and hepatopulmonary syndrome is not well defined. The advantage of TIPS is offset by a risk of developing hepatic encephalopathy, the most relevant post-procedural complication. Emerging data are addressing the determination the optimal time and patient selection for TIPS placement aiming at improving long-term treatment outcome. This review is aimed at summarizing the published data regarding the application of TIPS in the management of complications related to PH.

Entities:  

Keywords:  Ascites; Cirrhosis; Portal hypertension; Transjugular intrahepatic portosystemic shunts; Varices

Mesh:

Substances:

Year:  2014        PMID: 25493012      PMCID: PMC4258568          DOI: 10.3748/wjg.v20.i45.16996

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  134 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

Review 2.  Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.

Authors:  P Deltenre; P Mathurin; S Dharancy; R Moreau; P Bulois; J Henrion; F R Pruvot; O Ernst; J C Paris; D Lebrec
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

3.  Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

Authors:  Gennaro D'Amico; Angelo Luca; Alberto Morabito; Roberto Miraglia; Mario D'Amico
Journal:  Gastroenterology       Date:  2005-10       Impact factor: 22.682

Review 4.  The management of portal hypertension: rational basis, available treatments and future options.

Authors:  Jaime Bosch; Annalisa Berzigotti; Juan Carlos Garcia-Pagan; Juan G Abraldes
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

5.  Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis.

Authors:  P S Kamath; M Lacerda; D A Ahlquist; M A McKusick; J C Andrews; D A Nagorney
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

6.  Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax.

Authors:  M A Jeffries; S Kazanjian; M Wilson; J Punch; R J Fontana
Journal:  Liver Transpl Surg       Date:  1998-09

7.  "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.

Authors:  Christophe Bureau; Jean-Marie Péron; Laurent Alric; Joséphine Morales; Jérôme Sanchez; Karl Barange; Jean-Louis Payen; Jean-Pierre Vinel
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

8.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.

Authors:  Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

9.  Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliteration (BRTO).

Authors:  Wael Ea Saad; Cynthia Cindy Wagner; Allison Lippert; Abdullah Al-Osaimi; Mark G Davies; Alan H Matsumoto; John Fritz Angle; Stephen Caldwell
Journal:  Am J Gastroenterol       Date:  2013-08-13       Impact factor: 10.864

10.  Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome.

Authors:  J L Riegler; K A Lang; S P Johnson; J H Westerman
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

View more
  20 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Gastric Variceal Bleeding Caused by an Arterioportal Fistula Formation After TIPS and Related Complications.

Authors:  Shanhong Tang; Weizheng Zeng; Jianping Qin; Qianwen He; Xiaoling Wu; Xiaolei Zhou; Zhao Wang; Jianmei Zeng; Zhian Jin; Mingde Jiang
Journal:  Dig Dis Sci       Date:  2016-03-08       Impact factor: 3.199

4.  Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.

Authors:  Lauren A Shreve; Cathal O'Leary; Timothy W I Clark; S William Stavropoulos; Michael C Soulen
Journal:  J Gastrointest Oncol       Date:  2022-02

5.  Use of doppler ultrasound to predict need for transjugular intrahepatic portosystemic shunt revision.

Authors:  Nikki Duong; Marcus Healey; Kunal Patel; Brian J Strife; Richard K Sterling
Journal:  World J Hepatol       Date:  2022-06-27

6.  Portosystemic Shunts: Stable Utilization and Improved Outcomes, Two Decades After the Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Brandon C Perry; Sharon W Kwan
Journal:  J Am Coll Radiol       Date:  2015-09-26       Impact factor: 5.532

7.  Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Fuliang He; Shan Dai; Zhibo Xiao; Lei Wang; Zhendong Yue; Hongwei Zhao; Mengfei Zhao; Qiushi Lin; Xiaoqun Dong; Fuquan Liu
Journal:  Biomed Res Int       Date:  2016-11-15       Impact factor: 3.411

Review 8.  Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease.

Authors:  Oana Nicoară-Farcău; Ioana Rusu; Horia Stefănescu; Marcel Tanțău; Radu Ion Badea; Bogdan Procopeț
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

9.  Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice.

Authors:  Gianni Testino
Journal:  Clujul Med       Date:  2017-10-20

10.  Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension.

Authors:  Pei-Jing Cui; Jing Yao; Yin Zhu; Zheng-Yun Zhang; Jun Yang
Journal:  Gastroenterol Res Pract       Date:  2017-08-10       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.